‘You have to get up on the podium’: Incoming BIO chair Paul Hastings on diversity, drug pricing and working with the FDA

Amber Tong

Paul Hastings’ day job as CEO of Nkarta has him talking about natural killer cells and their potential applications in cancer. But throughout the pandemic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

‘You have to get up on the podium’: Incoming BIO chair Paul Hastings on diversity, drug pricing and working with the FDA

Amber Tong

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

US drugs rely heavily on ingredients made overseas, new report shows

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

Eli Lilly reports first Phase 3 data for oral GLP-1, posting a win in diabetes

Netherlands pours $1.5B into biotech in pursuit of global leadership ambitions

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

‘You have to get up on the podi­um’: In­com­ing BIO chair Paul Hast­ings on di­ver­si­ty, drug pric­ing and work­ing with the FDA

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

‘You have to get up on the podium’: Incoming BIO chair Paul Hastings on diversity, drug pricing and working with the FDA